These findings unequivocally establish the significant role of PLK1 in the pathogenesis of Middle Eastern BC and underscore the potential for combined PLK1 and PARP inhibitor therapy to extend its use beyond BC cases lacking BRCA. This evidence concerns the gene PLK1 and breast cancer.